Cell therapy in kidney disease: Cautious optimism... but optimism nonetheless

Peritoneal Dialysis International

Volumn 27, Issue SUPPL. 2, 2007, Pages

  Zenovich, Andrey G ^a   Taylor, Doris A ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

End stage renal disease; Kidney disease; Stem cells

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; ELECTROLYTE; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT ERYTHROPOIETIN;

ACUTE KIDNEY FAILURE; BLOOD VOLUME; CARDIOVASCULAR DISEASE; CELL POPULATION; CELL THERAPY; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; ENDOTHELIUM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INFECTION; INFLAMMATION; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MORBIDITY; MORTALITY; NONHUMAN; NUTRIENT; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; STEM CELL; TISSUE REPAIR;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; EPITHELIAL CELLS; HUMANS; INFLAMMATION; KIDNEY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; PERITONEAL DIALYSIS; QUALITY OF LIFE; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 35748977949     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (102)

1. Owen WF Jr. Patterns of care for patients with chronic kidney disease in the United States: dying for improvement. J Am Soc Nephrol 2003; 14(Suppl 2):S76-80.
2. Kundhal K, Lok CE. Clinical epidemiology of cardiovascular disease in chronic kidney disease. Nephron 2005; 101: c47-52.
3. Delisle H. Early nutritional inftuences on obesity, diabetes and cardiovascular disease risk. Matern Child Nutr 2005; 1:128-9.
4. Atilla K, Vasan RS. Prehypertension and risk of cardiovascular disease. Expert Rev Cardiovasc Ther 2006; 4:111-17.
5. Meigs 2B, Wilson PW, Fox CS, Vasan RS, Nathan DM, Sullivan LM, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease, J Clin Endocrinol Metab 2006; 91:2906-12.
6. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113:e85-151.
7. Nissenson AR, Pereira BJ, Collins AJ, Steinberg EP. Prevalence and characteristics of individuals with chronic kidney disease in a large health maintenance organization. Am J Kidney Dis 2001; 37:1177-83.
8. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96:1420-5.
9. Chiurchiu C, Remuzzi G, Ruggenenti P. Angiotensin-converting enzyme inhibition and renal protection in non-diabetic patients: the data of the meta-analyses. J Am Soc Nephrol 2005; 16(Suppl 1):S58-63.
10. McCullough PA, Sandberg KR, Yee J, Hudson MP. Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease. J Renin Angiotensin Aldosterone Syst 2002; 3:188-91.
11. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002; 61:297-304.
12. Hynes DM, Stroupe KT, Kaufman JS, Reda DJ, Peterman A, Browning MM, et al. Adherence to guidelines for ESRD anemia management. Am J Kidney Dis 2006; 47:455-61.
13. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 2003; 42:201-8.
14. Nissenson AR, Agarwal R, Allon M, Cheung AK, Clark W, Depner T, et al. Improving outcomes in CKD and ESRD patients: carrying the torch from training to practice. Semin Dial 2004; 17:380-97.
15. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352:1685-95.
16. Ross R. The pathogenesis of atheroscterosis: a perspective for the 1990s. Nature 1993; 362:801-9.
17. Dimmeler S, Haendeler J, Galle J, Zeiher AM. Oxidized low-density lipoprotein induces apoptosis of human endothelial cells by activation of CPP32-like proteases. A mechanistic clue to the 'response to injury' hypothesis. Circulation 1997; 95:1760-3.
18. Sun P, Dwyer KM, Merz CN, Sun W, Johnson CA, Shircore AM, et al. Brood pressure, LDL cholesterol, and intima-media thickness: a test of the "response to injury" hypothesis of atheroscterosis. Arterioscl Thromb Vasc Biol 2000; 20:2005-10.
19. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Sac Nephrol 2004; 15:1983-92.
20. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340:115-26.
21. Bhagat K, Vallace P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 1997; 96:3042-7.
22. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101:948-54.
23. Targonski PV, Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Lerman A. Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation 2003; 107:2805-9.
24. Gotdschmidt-Clermont PJ, Creager NA, Losordo DW, Lam GK, Wassef M, Dzau VJ. Atherosclerosis 2005: recent discoveries and novel hypotheses. Circulation 2005; 112: 3348-53.
25. Dursun B, Edelstein CL. Acute renal failure. Am J Kidney Dis 2005; 45:614-18.
26. Zager RA, Johnson AC, Lund S, Hanson SY, Abrass CK. Levosimendan protects against experimentat endotoxemic acute renal failure. Am J Physiol Renal Physiol 2006; 290:F1453-62.
27. Nakajima A, Ueda K, Takaoka M, Kurata H, Takayama J, Ohkita M, et al. Effects of pre- and post-ischemic treatments with FK409, a nitric oxide donor, on ischemia/reperfusion-induced renal injury and endothelin-1 production in rats. Biol Pharm Bull 2006; 29:577-9.
28. Tirkey N, Kaur G, Vij G, Chopra K. Curcumin, a diferuloyl-methane, attenuates cyclosporine-induced renal dysfunction and oxidative stress in rat kidneys. BMC Pharmacol 2005; 5:15.
29. Breen D, Bihari D. Acute renal failure as a part of multiple organ failure: the slippery stope of critical illness. Kidney Int 1998; 53(Suppl 66):S25-33.
30. Devarajan P. Cellular and molecular derangements in acute tubular necrosis. Curr Opin Pediatr 2005; 17:193-9.
31. Brodsky SV, Yamamoto T, Tada T, Kim B, Chen J, Kajiya F, et al. Endothelial dysfunction in ischemic acute renal failure: rescue by transplanted endothelial cells. Am J Physiol Renal Physiol 2002; 282:F1140-9.
32. Molitoris BA, Sutton TA. Endothelial injury and dysfunction: role in the extension phase of acute renal failure. Kidney Int 2004; 66:496-9.
33. Wiel E, Vallet B, ten Cate H. The endothelium in intensive care. Crit Care Clin 2005; 21:403-16.
34. Textor SC. Pathophysiology of renal failure in renovascular disease. Am J Kidney Dis 1994; 24:642-51.
35. London GM. Cardiovascular disease in chronic renal failure: pathophysiologic aspects. Semin Dial 2003; 16: 85-94.
36. Kaysen GA, Eiserich JP. Characteristics and effects of inflammation in end-stage renal disease. Semin Dial 2003; 16:438-46.
37. Himmelfarb J, McMonagle E, McMenamin E. Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int 2000; 58:2571-8.
38. Rysz J, Banach M, Cialkowska-Rysz A, Stolarek R, Barylski M, Drozdz J, et al. Blood serum levels of IL-2, IL-6, IL-8, TNF-α and IL-1β in patients on maintenance hemodialysis. Cell Mol Immunol 2006; 3:151-4.
39. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterotemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998; 32:107-14.
40. Zoccali C. Endothelial damage, asymmetric dimethyl-arginine and cardiovascular risk in end-stage renal disease. Blood Purif 2002; 20:469-72.
41. Diaz-Buxo JA, Woods HF. Protecting the endothelium: a new focus for management of chronic kidney disease. Hemodiol Int 2006; 10:42-8.
42. Aguilera A, Sanchez-Tomero JA, Bajo MA, Ruiz-Caravaca ML, Alvarez V, del Peso G, et al. Malnutrition-inflammation syndrome is associated with endothelial dysfunction in peritoneal dialysis patients. Adv Perit Dial 2003; 19: 240-5.
43. Coca SG, Perazella MA. Adverse cardiorenal effects of aldosterone: is aldosterone antagonism beneficial? Expert Rev Cardiavasc Ther 2005; 3:497-512.
44. Nakashima H, Suzuki H, Ohtsu H, Chao JY, Utsunomiya H, Frank GD, et al. Angiotensin II regulates vascular and endothetial dysfunction: recent topics of angiotensin II type-1 receptor signaling in the vasculature. Curr Vasc Pharmacol 2006; 4:67-78.
45. Denton MD, Davis SF, Baum MA, Melter M, Reinders ME, Exeni A, et al. The role of the graft endothelium in transplant rejection: evidence that endothetial activation may serve as a clinical marker for the development of chronic rejection. Pediatr Transplant 2000; 4:252-60.
46. Cailhier JF, Laptante P, Hebert MJ. Endothelial apoptosis and chronic transplant vasculopathy: recent results, novel mechanisms. Am J Transplant 2006; 6:247-53.
47. Bussolati B, Bruno S, Grange C, Buttiglieri S, Deregibus MC, Cantina D, et al. Isolation of renal progenitor cells from adult human kidney. Am J Pathol 2005; 166:545-55.
48. low/ side population cells isolated from adult rat kidney. Kidney Int 2004; 65:1604-14.
49. Haller H, de Groot K, Bahlmann F, Elger M, Riser D. Stem cells and progenitor cells in renal disease. Kidney Int 2005; 68:1932-6.
50. Imai E, Ito T. Can bone marrow differentiate into renal cells? Pediatr Nephrol 2002; 17:790-4.
51. Schachinger V, Zeiher A. Stem cells and cardiovascular and renal disease: today and tomorrow. J Am Soc Nephrol 2005; 16(Suppl 1):S2-6.
52. Min/+ mice. Cancer Res 2006; 66:57-61.
53. Alexis NE, Becker S, Bromberg PA, Devlin R, Peden DB. Circulating CD11b expression correlates with the neutrophil response and airway mCD14 expression is enhanced following ozone exposurein humans. Clin Immunol 2004; 111:126-31.
54. Gluck J, Rogala B, Mazur B. Intracellular production of IL-2, IL-4 and IFN-γ by peripheral blood CD3+ cells in intermittent allergic rhinitis. Inflamm Res 2005; 54:91-5.
55. Muller-Ehmsen J, Scheid C, Grundmann F, Hirsch I, Turan G, Tossios P, et al. The mobilization of CD34 positive mononuclear cells after myocardial infarction is abolished by revascularization of the culprit vessel. Int J Cardiol 2005; 103:7-11.
56. Goon PK, Boos CJ, Lip GY. Circulating endothelial cells: markers of vascular dysfunction. Clin Lab 2005; 51:531-8.
57. Cho HJ, Kim HS, Lee MM, Kim DH, Yang HJ, Hur J, et al. Mobilized endothelial progenitor cells by granulocyte-macrophage colony-stimulating factor accelerate reendothelialization and reduce vascular inflammation after intravascular radiation. Circulation 2003; 108: 2918-25.
58. Kunz G, Liang G, Cuculoski F, Gregg D, Vata K, Shaw L, et al. Circulating endothetial progenitor cells predict coronary artery disease severity. Am Heart J 2006; 152:190-5.
59. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, Wang T, Gregg D, Ramaswami P, et al. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation 2003; 108: 457-63.
60. Kondo T, Hayashi M, Takeshita K, Numaguchi Y, Kobayashi K, Iino S, et al. Smoking cessation rapidly increases circulating progenitor cells in peripheral blood in chronic smokers. Arterioscl Thromb Vasc Biol 2004; 24:1442-7.
61. Brevetti G, Silvestro A, Di Giacomo S, Bucur R, Di Donato A, Schiano V, et al. Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but notto classic risk factors and atherosclerotic burden. J Vasc Surg 2003; 38:374-9.
62. Landry D, Oliver J. Blood pressure instability during hemodialysis. Kidney Int 2006; 69:1710-11.
63. Piraino B. Peritoneal dialysis infections recommendations. Contrib Nephrol 2006; 150:181-6.
64. Anversa P, Kajstura J, Leri A, Bolli R. Life and death of cardiac stem cells: a paradigm shift in cardiac biology. Circulation 2006; 113:1451-63.
65. Challen G, Martinez G, Davis M, Taylor D, Crowe M, Teasdale R, et al. Identifying the molecular phenotype of renal progenitor cells. J Am Soc Nephrol 2004; 15:2344-57.
66. Osafune K, Takasato M, Kispert A, Asashima M, Nishinakamura R. Identification of multipotent progenitors in the embryonic mouse kidney by a novel colony-forming assay. Development 2006; 133:151-61.
67. Oliver J, Maarouf O, Cheema F, Martens T, Al-Awqati Q. The renal papilla is a niche for adult kidney stem cells. J Clin Invest 2004; 114:795-804.
68. Patschan D, Krupincza K, Patschan S, Zhang Z, Hamby C, Goligorsky M. Dynamics of mobilization and homing of endothetial progenitor cells after acute renal ischemia: modulation by ischemic preconditioning. Am J Physiol Renal Physiol 2006; 291:F176-85.
69. Patschan D, Plotkin M, Goligorsky M. Therapeutic use of stem and endothelial progenitor cells in acute renal injury: ca ira. Curr Opin Pharmacol 2006; 6:176-83.
70. Arriero M, Brodsky S, Gealekman O, Lucas P, Goligorsky M. Adult skeletal. muscle stem cells differentiate into endothelial lineage and ameliorate renal dysfunction after acute ischemia. Am J Physiol Renal Physiol 2004; 287: F621-7.
71. Lin F, Cordes K, Li L, Hood L, Couser WG, Shankland SJ, et al. Hematopoietic stem cells contribute to the regeneration of renal tubules after renalischemia-reperfusion injury in mice. J Am Soc Nephrol 2003; 14:1188-99.
72. Togel F, Isaac J, Westenfelder C. Hematopoietic stem cell mobilization-associated granulocytosis severely worsens acute renal failure. J Am Soc Nephrol 2004; 15:1261-7.
73. Iwasaki M, Adachi Y, Minamino K, Suzuki Y, Zhang Y, Okigaki M, et al. Mobilization of bone marrow cells by G-CSF rescues mice from cisplatin-induced renal failure, and M-CSF enhances the effects of G-CSF. J Am Soc Nephrol 2005; 16: 658-66.
74. Nishida M, Fujimoto S, Toiyama K, Sato H, Hamaoka K. Effect of hematopoietic cytokines on renal function in cisptatin-induced ARF in mice. Biochem Biophys Res Commun 2004; 324:341-7.
75. Morigi M, Imberti B, Zoja C, Coma D, Tomasoni S, Abbate M, et al. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol 2004; 15:1794-804.
76. Togel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C. Administered mesenchymalstem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005; 289:F31-42.
77. Choi J, Kim K, Huh W, Kim B, Byun J, Suh W, et al. Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscl Thromb Vasc Biol 2004; 24:1246-52.
78. Rodriguez M, Canadillas S, Lopez I, Aguilera-Tejero E, Almaden Y. Regulation of parathyroid function in chronic renal failure. J Bone Miner Metab 2006; 24:164-8.
79. Macdougall I, Cooper A. Hyporesponsiveness to erythropoietic therapy due to chronic inflammation. Eur J Clin Invest 2005; 35(Suppl 3):32-5.
80. de Groot K, Bahlmann F, Sowa J, Koenig 3, Menne J, Haller H, et al. Uremia causes endothelial progenitor cell deficiency. Kidney Int 2004; 66:641-6.
81. Glaser M. Growth characteristics of circulating hematopoietic progenitors in terminal renal failure. Med Sci Monit 2006; 12:CR113-17.
82. Bahlmann F, de Groot K, Spandau O, Landry A, Hertel B, Duckert T, et al. Erythropoietin regulates endothelial progenitor cells. Blood 2004; 103:921-6.
83. Eizawa T, Murakami Y, Matsui K, Takahashi M, Muroi K, Amemiya M, et al. Circulating endothelial progenitor cells are reduced in hemodialysis patients. Curr Med Res Opin 2003; 19:627-33.
84. Herbrig K, Pistrosch F, Oelschlaegel U, Wichmann G, Wagner A, Foerster S, et al. Increased total number but impaired migratory activity and adhesion of endothelial progenitor cells in patients on long-term hemodialysis. Am J Kidney Dis 2004; 44:840-9.
85. Chan C, Li S, Verma S. Nocturnal hemodialysis is associated with restoration of impaired endothelial progenitor cell biology in end-stage renal disease. Am J Physiol Renal Physiol 2005; 289:F679-84.
86. Ronco C, Amerling R, Dell'aquila R, Rodighiero M, Di Loreto P. Evolution of technology for automated peritoneal dialysis. Contrib Nephrol 2006; 150:291-309.
87. Finkelstein F, Finkelstein S, Troidle L. The role of chronic peritoneal dialysis in the management of the patient with chronic kidney disease. Contrib Nephrol 2006; 150:235-9.
88. Sugimoto H, Mundel T, Sund M, Xie L, Cosgrove D, Kalluri R. Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease. Proc Natl Acad Sci USA 2006; 103:7321-6.
89. Uchimura H, Marumo T, Takase O, Kawachi H, Shimizu F, Hayashi M, et al. Intrarenal injection of bone marrow-derived angiogenic cells reduces endothelial injury and mesangial cell activation in experimental glomerulone-phritis. J Am Soc Nephrol 2005; 16:997-1004.
90. de Groot K, Bahtmann F, Bahtmann E, Menne J, Haller H, Fliser D. Kidney graft function determines endothelial progenitor cell number in renal transplant recipients. Transplantation 2005; 79:941-5.
91. Steiner S, Winkelmayer W, Kleinert J, Grisar J, Seidinger D, Kopp C, et al. Endothelial progenitor cells in kidney transplant recipients. Transplantation 2006; 81:599-606.
92. Soler M, Martinez-Estrada O, Puig-Mari J, Marco-Feliu D, Oliveras A, Vila J, et al. Circulating endothelial progenitor cells after kidney transplantation. Am J Transplant 2005; 5:2154-9.
93. Nikolovski J, Gulari E, Humes H. Design engineering of a bioartificial renal tubule cell therapy device. Cell Transplant 1999; 8:351-64.
94. MacKay S, Funke A, Buffington D, Humes H. Tissue engineering of a bioartificial renal tubule. ASAIO J 1998; 44: 179-83.
95. Humes H, Buffington D, MacKay S, Funke A, Weitzel W. Replacement of renal function in uremic animals with a tissue-engineered kidney. Nat Biotechnol 1999; 17:451-5.
96. Humes H, Weitzel W, Bartlett R, Swaniker F, Paganini E, Luderer J, et al. Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure. Kidney Int 2004; 66:1578-88.
97. Campean V, Neureiter D, Varga I, Runk F, Reiman A, Garlichs C, et al. Atherosclerosis and vascular calcification in chronic renal failure. Kidney Blood Press Res 2005; 28: 208-9.
98. Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006; 355:1210-21.
99. Siminiak T, Fiszer D, Jerzykowska O, Grygielska B, Rozwadowska N, Kalmucki P, et al. Percutaneous trans-coronary-venous transplantation of autologous skeletal myoblasts in the treatment of post-infarction myocardial contractility impairment: the POZNAN trial. Eur Heart J 2005; 26:1188-95.
100. Kawada H, Fujita J, Kinjo K, Matsuzaki Y, Tsuma M, Miyatake H, et al. Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood 2004; 104:3581-7.
101. Schuster MD, Kocher AA, Seki T, Martens TP, Xiang G, Homma S, et al. Myocardial neovascularization by bone marrow angioblasts results in cardiomyocyte regeneration. Am J Physiol Heart Circ Physiol 2004; 287:H525-32.
102. Jordan C, Guzman M, Noble M. Cancer stem cells. N Engl J Med 2006; 355:1253-61.